Date of this Version
9-1-2021
Document Type
Article
Abstract
Lipids represent a valuable target for metabolomic studies since altered lipid metabolism is known to drive the pathological changes in cardiovascular disease (CVD). Metabolomic technologies give us the ability to measure thousands of metabolites providing us with a metabolic fingerprint of individual patients. Metabolomic studies in humans have supported previous findings into the pathomechanisms of CVD, namely atherosclerosis, apoptosis, inflammation, oxidative stress, and insulin resistance. The most widely studied classes of lipid metabolite biomarkers in CVD are phos-pholipids, sphingolipids/ceramides, glycolipids, cholesterol esters, fatty acids, and acylcarnitines. Technological advancements have enabled novel strategies to discover individual biomarkers or panels that may aid in the diagnosis and prognosis of CVD, with sphingolipids/ceramides as the most promising class of biomarkers thus far. In this review, application of metabolomic profiling for biomarker discovery to aid in the diagnosis and prognosis of CVD as well as metabolic abnormalities in CVD will be discussed with particular emphasis on lipid metabolites.
DOI
10.3390/metabo11090621
Recommended Citation
McGranaghan, Peter; Kirwan, Jennifer A.; Garcia-Rivera, Mariel A.; Pieske, Burkert; Edelmann, Frank; Blaschke, Florian; Appunni, Sandeep; Saxena, Anshul; Rubens, Muni; Veledar, Emir; and Trippel, Tobias Daniel, "Lipid metabolite biomarkers in cardiovascular disease: Discovery and biomechanism translation from human studies" (2021). All Faculty. 331.
https://digitalcommons.fiu.edu/all_faculty/331